Document is current
Any future updates will be listed below
-
Authors
Marigny, Céline
Revet, Gaëlle
Berger, Anne
Boulch, Morgane
Mougenot, Nathalie
Li, Zhenlin
Corre, Béatrice
Lemaitre, Mégane
Bois, Axelle
Castelli, Clara
Collombat, Victor
Parlakian, Ara
Perier, Marie-Cécile
Bot, Adrian
Epstein, Jonathan A.
Lafuste, Peggy
Hagege, Albert
Aghajanian, Haig
Cochain, Clément
Bousso, Philippe
Agbulut, Onnik
Menasché, Philippe
-
Funding
Funding for this research was provided by:
Labex Revive (ANR-10-LABX-73)
Agence Nationale de la Recherche (ANR-23-CPJ1-0134-01)
German Research Foundation (453989101)
Sorbonne Université
CNRS
Institut National de la Santé et de la Recherche Médicale
- License Information
-
More Information
Article History
Received: 2 November 2025
Accepted: 10 April 2026
First Online: 30 April 2026
Declarations
:
: All animal procedures were performed in accordance with National and European legislations, under the license APAFIS #34549 (title of the approved project: Evaluation des CAR-T cells pour traiter la fibrose dans la Dystrophie Musculaire de Duchenne dans un modèle murin; date of approval: 2022, December 7) (French Ministry of National Education, Higher Education and Research). DBA/2J and D2. mdx (DBA/2J background) mice were obtained from Charles Rivers and The Jackson Laboratory, respectively.
: Not applicable.
: This project was partially funded by Capstan Therapeutics. J-A.E., P.M., Ad.B. and H.A. held equities in Capstan Therapeutics and Ad.B. and H.A were employees of Capstan before the company was acquired by Abbvie.
